Clinical Laboratory News of the Day – New Immunoassays Allow Early Diagnosis of Antiphospholipid Syndrome – Immunology

New immunoassays allow early diagnosis of antiphospholipid syndrome

Written by the LabMedica editorial team in Spanish
Updated March 19, 2024

Antiphospholipid syndrome (APS) is an autoimmune disorder that usually manifests as venous or arterial thrombosis and/or pregnancy loss. APS can be difficult to diagnose because its symptoms often resemble those of other diseases. Timely diagnosis is essential to avoid complications, unnecessary medical procedures, and increased health care costs. Now, a new pair of reagents may allow early diagnosis of APS, a difficult-to-diagnose autoimmune disease.

Aptiva APS immunoglobulin G (IgG) and immunoglobulin M (IgM) reagents from Werfen (Barcelona, ​​Spain) are immunoassays that use Aptiva's particle-based multiple analysis technology (PMAT) for the semi-quantitative determination of anti-cardiolipin (aCL), IgG and anti-beta antibodies. IgM. 2 glycoprotein 1 (aβ2GP1) in human serum and citrated plasma. It serves as a diagnostic aid for both primary and secondary APS, along with other laboratory findings.

Image: Aptiva uses Particle-Based Multi-Analysis Technology (PMAT) (Image courtesy of Werfen)

The Aptiva system is a fully automated multi-analyte system and represents the latest advances in high-throughput analyzers for autoimmunity and immunology laboratories. Using PMAT, Aptiva can process up to 120 SAF tests per hour, allowing laboratories to handle their workload more efficiently and with less manual intervention. Werfen recently announced that it has achieved CE (Conformité Européenne) marking for its Aptiva APS IgG and IgM reagents. These new reagents not only complement Werfen's existing Aptiva core reagents for the treatment of celiac disease and connective tissue disease (CTE), but also expand the range of CE-marked analytes that can be detected by Aptiva to a total of 19 analytes.

“Early diagnosis is critical to preventing complications, as well as unnecessary procedures and increased health care costs,” said Michael Mahler, Ph.D., vice president of research and development at Werfen. “Aptiva APS IgG and APS IgM provide expanded information for clinicians to help diagnose and treat patients with autoimmune diseases.”

Related links:
Vervain